Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells

Anticancer Research

Volumn 19, Issue 1 A, 1999, Pages 221-228

  Lei, Wendong ^a   Mayotte, Jane E ^a   Levitt, Mark L ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Chemosensitivity; EGFR; Non small cell lung cancer; Tyrosine kinase inhibitors

Indexed keywords

CISPLATIN; DNA FRAGMENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; GENISTEIN; GLYCOPROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TYRPHOSTIN;

APOPTOSIS; ARTICLE; CELL DEATH; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; ENZYME INHIBITORS; GENISTEIN; HUMANS; LUNG NEOPLASMS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 0032896495     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Parker SL, Tong T, Bolden S and Wingo PA: Cancer statistics, 1996. CA. Cancer J Clin 46: 5-27, 1996.
2. Minna JD, Pass J, Glatstein E and Ihde DC: Cancer of the lung. In: Cancer: principles and practice of oncology (De Vita VTJ, Hellman S and Rosenberg SA, eds). Lippincott JB, 1989, pp 591-705
3. Boring CC, Squires TS, Tong T and Montgomery S: Cancer statistics, 1994. CA. Cancer J Clin 44: 7-26, 1994.
4. Carpenter G: Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 56: 881-914, 1987.
5. Fantl WJ, Johnson DE and Williams LT: Signalling by receptor tyrosine kinases. Annu Rev Biochem 62: 453-481, 1993.
6. Carpenter G and Cohen S: Epidermal growth factor. J Biol Chem 265; 7704-7712, 1990.
7. Cowley G, Smith JA, Gusterson B, Hendler F and Ozanne B: The amount of EGF receptors is elevated on squamous cell carcinomas. In: Cancer Cells ( Levine A, VandeWoude G, Topp W and Watson JD. eds). New York, 1984, pp 5-10.
8. Ozanne B, Richards CS, Hendler F, Burns D and Gusterson B: dver-expression of the EGF receptor is a hallmark of squamous cell carcinomas. J Pathol 149: 9-14, 1986.
9. Neal DE, Sharples L, Smith K, Fennelly J, Hall RR and Harris AL: The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65: 1619-1625, 1990.
10. Gullick WJ: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 47: 87-98, 1991.
11. Kohler M, Bauknecht T, Grimm M, Birmelin G, Kommoss F and Wagner E: Epidermal growth factor receptor and transforming growth factor alpha expression in human ovarian carcinomas. Eur J Cancer 28A: 1432-1437, 1992.
12. Haeder M, Rotsch M, Bepler G, Hennig C, Havemann K, Heimann B and Moelling K: Epidermal growth factor receptor expression in human lung cancer cell lines. Cancer Res 48: 1132-1136, 1988.
13. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi H, Angeletti CA, Pingitore R, Pepe S, Basolo F and Bevilacqua G: Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer 31A: 178-183, 1995.
14. Veale D, Kerr N, Gibson GJ, Kelly PJ and Harris AL: The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 68: 162-165, 1993.
15. Dickstein BM, Wosikowski K and Bates SE: Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor. Mol Cell Endocrinol 110: 205-211, 1995.
16. Ogawa J, Iwazaki M, Inoue H, Koide S and Shohtsu A: Immunohistochemical study of glutathione-related enzymes and proliferative antigens in lung cancer. Relation to cisplatin sensitivity. Cancer 71: 2204-2209, 1993.
17. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH, Jr and Mendelsohn J Antitumor effects of doxoruhicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85: 1327-1333, 1993.
18. Fan Z, Baselga J, Masui H and Mendelsohn J: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53: 4637-4642, 1993.
19. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M and Fukami Y: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262: 5592-5595, 1987.
20. Gazit A, Chen J, App H, McMahon G, Hirth P, Chen I and Levitzki A: Tyrphostins IV-highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines. Bioorg. Med Chem 4: 1203-1207, 1995.
21. Ward WH, Cook PN, Slater AM, Davies DH, Holdgate GA and Green LR: Epidermal growth factor receptor tyrosine kinase: Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem Pharmacol 48: 659-666, 1994.
22. Penar PL, Khoshyomn S, Bhushan A and Tritton TR: Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain. Neurosurgery 40: 141-151, 1997.
23. Levitzki A and Gazit A: Tyrosine kinase inhibition: an approach to drug development. Science 267: 1782-1788, 1995.
24. Osherov N and Levitzki A: Epidermal-growth-factor-dependent activation of the src-family kinases. Eur J Biochem 225: 1047-1053, 1994.
25. Ben-Bassat H, Rosenbaum-Mitrani S, Hartzstark Z, Shlomai, Z, Kleinberger-Doron N, Gazit A, Plowman G, Levitzki R, Tsvieli R and Levitzki A: Inhibitors of epidermal growth factor receptor kinase and of cyclin-dependent kinase 2 activation induce growth arrest, differentiation, and apoptosis of human papilloma virus 16-immortalized human keratinocytes. Cancer Res 57: 3741-3750, 1997.
26. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, Todd DG, Valerie K, Kavanagh BD, Contessa JN, Rorrer WK and Chen PB: Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15: 1191-1197, 1997.
27. Levitzki A, Gazit A, Osherov N, Posner I and Gilon C: Inhibition of protein-tyrosine kinases by tyrphostins. Methods Enzymol 201: 347-361, 1991.
28. Enari M, Talanian RV, Wong WW and Nagata S: Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 380: 723-726, 1996.
29. Enari M, Hug H and Nagata S: Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 375: 78-81, 1995.
30. Boudreau N, Sympson CJ, Werb Z and Bissell MJ: Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 267: 891-893, 1995.
31. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG and Earnshaw WC: Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371: 346-347, 1994.
32. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M and Lazebnik YA: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37-43, 1995.
33. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS and Dixit VM: Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81: 801-809, 1995.
34. Scanlon KJ, Kashani-Sabet M, Miyachi H, Sowers LC and Rossi J: Molecular basis of cisplatin resistance in human carcinomas: model systems and patients. Anticancer Res 9: 1301-1312, 1989.
35. Sklar MD and Prochownik EV: Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc. Cancer Res 51: 2118-2123, 1991.
36. Niimi S, Nakagawa K, Yokota J, Tsunokawa Y, Nishio K, Terashima Y, Shibuya M, Terada M and Saijo N: Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes. Br J Cancer 63: 237-241, 1991.
37. Isonishi S, Horn DK, Thiebaut FB, Mann SC, Andrews PA, Basu A, Lazo JS, Eastman A and Howell SB: Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin. Cancer Res 51: 5903-5909, 1991.
38. Tsai CM, Chang KT, Perng RP, Mitsudomi T, Chen MH, Kadoyama C and Gazdar AF: Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression hut not with ras gene mutations. J Natl Cancer Inst 85: 897-901, 1993.
39. Tsai CM, Yu D, Chang KT, Wu LH, Perng RP, Ibrahim NK and Hung MC: Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. J Natl Cancer Inst 87: 682-684, 1995.
40. Meyers MB, Merluzzi VJ, Spengler BA and Biedler JL: Epiderrnal'growth factor receptor is increased in multidrug-resistant Chinese hamster and mouse tumor cells. Proc Natl Acad Sci USA 83: 5521-5525, 1986.
41. Nuti M, Zupi G, D'Agnano I, Turchi V, Candiloro A and Frati L: Antigenic expression changes occurring in adriamycin resistant MCF-7 mammary carcinoma cells. Anticancer Res 11: 1225-1230, 1991.
42. Dickstein B, Valverius EM, Wosikowski K, Saceda M, Pearson JW, Martin MB and Bates SE: 19 Increased epidermal growth factor receptor in an estrogen-responsive, adriamycin-resistant MCF-7 cell line. J Cell Physiol 157: 110-118, 1993.
43. Meyers MB and Biedler JL: Evidence for reverse transformation in multidrug-resistant human neuroblastoma cells. Prog Clin Biol Res 271: 449-461, 1988.
44. Berns EM, Foekens JA, van Staveren IL, van Putten WL, de Koning HY. Portengen H and Klijn JG: Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 159: 11-18, 1995.
45. Vickers PJ, Dickson RB, Shoemaker R and Cowan KH: A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol Endocrinol 2: 886-892, 1988.
46. Meyers MB, Yu P and Mendelsohn J: Crosstalk between epidermal growth factor receptor and P-glycoprotein in actinomycin D-resistant Chinese hamster lung cells. Biochem Pharmacol 46: 1841-1848, 1993.
47. Traganos F, Ardelt B, Halko N, Bruno S and Darzynkiewicz Z: Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells. Cancer Res 52: 6200-6208, 1992.
48. Constantinou A, Kiguchi and Huberman E: Induction of differentiation and DNA strand breakage in human HL-60 and K-562 leukemia cells by genistein. Cancer Res 50: 2618-2624, 1990.
49. Pagliacci MC, Smacchi, M, Migliorati G, Grignani F, Riccardi C and Nicoletti I: Growth-inhibitory effects of the natural phyto-oestrogen genistein in MCF-7 human breast cancer cells. Eur J Cancer 30A: 1675-1682, 1994.
50. Tsai CM, Levitzki A, Wu LH, Chang KT, Cheng CC, Gazit A and Perng RP: Enhancement of 20 chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. Cancer Res 56: 1068-1074, 1996.
51. White E: Life, death, and the pursuit of apoptosis. Genes Dev 10: 1-15, 1996.
52. Hale AJ, Smith CA, Sutherland LC, Stoneman VE, Longthorne VL, Culhane AC and Williams GT: Apoptosis: molecular regulation of cell death. Eur J Biochem 236: 1-26, 1996.
53. Nagata S and Golstein P: The Fas death factor. Science 267: 1449-1456, 1995.
54. Kerr JF, Wyllie AH and Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239-257, 1972.
55. Wyllie AH: Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284: 555-556, 1980.
56. Wyllie AH, Morris RG, Smith AL and Dunlop D: Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol 142: 67-77, 1984.
57. Fernandes Alnemri T, Litwack G and Alnemri ES: CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 269: 30761-30764, 1994.